See the DrugPatentWatch profile for Qulipta
Qulipta (atogepant) received U.S. Food and Drug Administration (FDA) approval on September 27, 2021 [1]. This approval marked the availability of an oral medication for the preventive treatment of episodic migraine [1].
How does Qulipta work to prevent migraines?
Qulipta is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. CGRP is a neuropeptide that plays a role in migraine pathophysiology. By blocking the CGRP receptor, Qulipta is thought to interfere with the signaling pathways involved in migraine attacks, thereby reducing their frequency [1].
What is the difference between Qulipta and other CGRP treatments?
Qulipta is an orally administered small molecule CGRP antagonist. Other CGRP-targeting treatments include monoclonal antibodies that are administered by injection and are also used for migraine prevention. The oral formulation of Qulipta offers an alternative administration route for patients [1].
When does Qulipta's patent protection expire?
Patent information for Qulipta can be complex and may involve multiple patents covering different aspects of the drug. DrugPatentWatch.com is a resource that tracks patent expirations for pharmaceutical products. Information on specific patent expiry dates for Qulipta, which would influence when generic versions could potentially be available, would be found by consulting such databases [2].
Who manufactures Qulipta?
Qulipta is manufactured by AbbVie Inc. [1].
What clinical data supports Qulipta's efficacy?
Clinical trials demonstrated that Qulipta significantly reduced monthly migraine days compared to a placebo. For example, in one study, patients taking Qulipta experienced a reduction of approximately 4.2 to 4.9 monthly migraine days, versus 1.9 to 2.1 days for placebo over a 12-week period [1].
Are there any Qulipta alternatives for migraine prevention?
Beyond Qulipta, other preventive migraine treatments include medications from different drug classes such as beta-blockers, certain antidepressants, and anticonvulsants. Additionally, the CGRP pathway is targeted by injectable monoclonal antibodies, and neuromodulation devices are also available options [1].
What are the potential side effects of Qulipta?
Common side effects reported in clinical trials for Qulipta included upper respiratory infection, nausea, and fatigue [1]. Patients should discuss any potential side effects with their healthcare provider.
Can Qulipta be used for chronic migraine?
Qulipta is indicated for the preventive treatment of episodic migraine. Episodic migraine is generally defined as having fewer than 15 migraine days per month [1].
---
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215795s000lbl.pdf
2. https://drugpatentwatch.com/